News coverage about Apollo Endosurgery (NASDAQ:APEN) has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.257063503295 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.39 Per Share (americanbankingnews.com)
- Apollo Endosurgery (APEN) and Utah Medical Products (UTMD) Critical Contrast (americanbankingnews.com)
- Apollo Endosurgery Announces Conclusion of LAP-BAND® Low BMI Post-Approval Study (finance.yahoo.com)
- Apollo Endosurgery Inc (APEN) Expected to Post Quarterly Sales of $16.00 Million (americanbankingnews.com)
A number of equities analysts have recently issued reports on APEN shares. Northland Securities reiterated a “buy” rating and issued a $12.00 price target on shares of Apollo Endosurgery in a report on Tuesday, November 28th. Zacks Investment Research downgraded shares of Apollo Endosurgery from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th. ValuEngine upgraded shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, Roth Capital set a $10.00 price target on shares of Apollo Endosurgery and gave the company a “buy” rating in a report on Thursday, January 4th. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $9.44.
Apollo Endosurgery (NASDAQ:APEN) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.08). Apollo Endosurgery had a negative net margin of 42.35% and a negative return on equity of 64.48%. The company had revenue of $16.14 million during the quarter, compared to analysts’ expectations of $16.64 million. analysts forecast that Apollo Endosurgery will post -1.41 earnings per share for the current fiscal year.
In other Apollo Endosurgery news, Director Matthew S. Crawford bought 4,038 shares of the company’s stock in a transaction on Friday, March 9th. The stock was purchased at an average cost of $6.20 per share, for a total transaction of $25,035.60. Following the acquisition, the director now owns 53,715 shares of the company’s stock, valued at approximately $333,033. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Stonepine Capital, L.P. bought 22,845 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were acquired at an average price of $5.71 per share, with a total value of $130,444.95. Following the completion of the acquisition, the insider now directly owns 2,560,314 shares in the company, valued at approximately $14,619,392.94. The disclosure for this purchase can be found here. Insiders have acquired a total of 37,333 shares of company stock valued at $210,622 over the last 90 days. 74.20% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3299182/apollo-endosurgery-apen-earning-somewhat-favorable-media-coverage-report-shows.html.
About Apollo Endosurgery
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.